摘要
目的观察血清mi RNA-21在肾癌患者中表达的差异,以筛选肾癌术后检测指标。方法提取32例肾癌患者(术前一次,术后6个月一次)、20例健康人群(对照组)及15例肾脏良性肿瘤患者血清,采用实时荧光定量聚合酶链反应(RT-q PCR)测量mi RNA-21在各组的差异表达。结果不同民族、性别和年龄水平的肾癌术前患者,其血清mi RNA-21的表达比较差异均无统计学意义(P>0.05),而血清mi RNA-21在肾癌术前组、对照组及肾脏良性肿瘤组之间比较差异有统计学意义(Z=27.658,P=0.001),两两比较结果显示:肾癌术前组与对照组比较(Z=肾细胞癌;微小RNA;血清;生物标志物5.072,P=0.000)、肾癌术前组与良性肿瘤组比较(Z=-2.5,P=0.012)、良性肿瘤与对照组比较(Z=-2.439,P=0.014)差异均有统计学意义;血清mi RNA-21在肾癌术前和术后6个月之间比较差异有统计学意义(Z=-2.674,P=0.007);血清mi RNA-21在肾癌术前组中高表达(术前组中位数0.34,良性肿瘤组中位数0.15,对照组中位数0.06),血清mi RNA-21在肾癌术后6个月的表达呈下调趋势(术前中位0.34,术后6个月中位数0.15)。mi RNA-21筛查肾癌的敏感度为90%、特异度为84.4%,ROC曲线下面积(AUC)为0.92。结论血清mi RNA-21在肾癌患者中高表达,其有可能成为肾癌诊断、术后检测的生化标志物。
Objective To investigate the changes in expression of serum miRNA-21 in patients with renal cell carcinoma （RCC） before and after surgery, and to identify detection indexes for renal cell carcinoma after surgery. Methods The expression of serum miRNA-21 was detected by real-time quantitative polymerase chain reaction （RT-qPCR） in a larger cohort, including 32 RCC patients （RCC group）, 20 healthy individuals （control group） and 15 patients with benign renal tumor （benign tumor group）. The RCC patients were detected preoperatively and 6 months postoperatively. Results Among RCC patients, there was no statistically significant differences in serum miRNA-21 expression between different ethnicity, gender and age （P〉0.05）. Significant differences existed in preoperative RCC patients, controls and patients with benign renal tumor （Z=27.536, P〈0.001）. Paired comparisons showed statistically significant differences between preoperative RCC patients and the controls （Z=-5.072, P〈0.001）, preoperative RCC patients and patients with benign renal tumor （Z=-2.5, P〈0.012）, controls and patients with benign renal tumor （Z=-2.439, P〈0.014）. Between preoperative and postoperative RCC patients, significant difference was found （Z=-2.684, P〈0.007）. Serum miRNA-21 expression level revealed an up-regulation in preoperative RCC patients （pre-operative RCC group, with a median of 0.34;benign renal tumor group, 0.15;control group, 0.06）, but it a down-regu-lation in postoperative RCC patients （preoperative RCC group, with a median of 0.34, postoperative RCC group, 0.15）. As a biochemical marker, miRNA-21 has sensitivity of 90%, specificity of 84.4%, with an area under the ROC curve （AUC） of 0.92. Conclusion The differences of serum miRNA-21 expression in a larger cohort （32 RCC pa-tients, 20 controls and 15 patients with benign renal tumor） are statistically significant. Therefore, serum miRNA-21 is expected to become a biochemical marker for the diagnosis and post-operational determination of RCC.
出处
《海南医学》
CAS
2015年第7期948-951,共4页
Hainan Medical Journal
基金
新疆维吾尔自治区自然科学基金(编号:2013211A101)
